Ausgabe 12/2019
Inhalt (9 Artikel)
Breast Cancer (B Overmoyer, Section Editor)
When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?
Lung Cancer (H Borghaei, Section Editor)
Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era
Alex Friedlaender, Giuseppe Luigi Banna, Lucio Buffoni, Alfredo Addeo
Palliative Medicine (A Jatoi, Section Editor)
The Role of Ablation in Cancer Pain Relief
Dimitrios K. Filippiadis, Steven Yevich, Frederic Deschamps, Jack W. Jennings, Sean Tutton, Alexis Kelekis
Palliative Medicine (A Jatoi, Section Editor)
Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era
Rachel Phelan, Hesham Eissa, Kerri Becktell, Neel Bhatt, Matthew Kudek, Brandon Nuechterlein, Lauren Pommert, Ryuma Tanaka, K. Scott Baker
Breast Cancer (B Overmoyer, Section Editor)
PI3K Inhibitors in Breast Cancer Therapy
Haley Ellis, Cynthia X. Ma
Breast Cancer (B Overmoyer, Section Editor)
When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab
Alexandra S. Zimmer, Neelima Denduluri
Melanoma (RJ Sullivan, Section Editor)
The Evolution of Adjuvant Therapy for Melanoma
Justine V. Cohen, Elizabeth I. Buchbinder
Melanoma (RJ Sullivan, Section Editor)
Primary Melanoma: from History to Actual Debates
Alessandro A. E. Testori, Stephanie A. Blankenstein, Alexander C. J. van Akkooi
Neuro-oncology (Y Umemura, Section Editor)
Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition
Peter Chei-way Pan, Aya Haggiagi